-
Anthera Soars 30% On Kidney Treatment Data
Wednesday, December 7, 2016 - 1:44pm | 335Read More...Shares of Anthera Pharmaceuticals Inc (NASDAQ: ANTH), a nano-cap bio-pharmaceutical company that focuses on developing and commercializing products to treat serious diseases, soared higher by more than 30 percent on Wednesday. Anthera announced on Tuesday positive data from its Phase 2 BRIGHT-...
-
Piper Jaffray Raises PT On Anthera Pharmaceuticals To $12
Monday, May 23, 2011 - 5:49am | 27Read More...Piper Jaffray has raised the price target on Anthera Pharmaceuticals (NASDAQ: ANTH) from $9 to $12 and maintains its Overweight rating.
-
Anthera Resumes Trial Testing On Lupus Patients While Starting On Other New Trials
Tuesday, January 11, 2011 - 10:06am | 202Read More...Piper Jaffray has published a research report on Anthera Pharmaceuticals (NASDAQ: ANTH) after the company resumed patient screening for its Phase IIb PEARL-SC lupus trial of A-623. In the report, Piper Jaffray writes "Anthera has resumed patient screening in the Phase IIb PEARL-SC lupus trial of A-...
